DMA.V - DiaMedica Therapeutics Inc.

YHD - YHD Delayed Price. Currency in USD
500,000.00
+1.16 (+0.00%)
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • GlobeNewswire

    DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting

    DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development: DM199 for Chronic Kidney Disease” at the Chronic Kidney Disease Drug Development (“CKD3”) summit in Boston on Tuesday May 7, 2019, at 1:30 Eastern Time. CKD3 is a uniquely focused conference that unites key opinion leaders to identify and discuss critical factors in determining the success of current chronic kidney disease (“CKD”) pipelines and evaluate new treatments that have the potential to significantly impact the standard of care for this serious unmet medical need. Leading experts from innovative biotechnology and pharmaceutical companies, academia and key service providers come together at the CKD3 summit to present comprehensive insight into the cutting-edge progress of CKD drug development research.

  • GlobeNewswire

    DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update

    Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute.

  • GlobeNewswire

    DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call

    MINNEAPOLIS, March 18, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March.

  • GlobeNewswire

    DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019

    MINNEAPOLIS, March 12, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The.

  • GlobeNewswire

    DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199.  The Phase 1b study, conducted in the US, is a multi-center, open label clinical trial to evaluate the safety, tolerability and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. “This study will assist in determining dose levels required to restore normal KLK1 protein levels in patients with CKD and provide additional insights about the specific CKD patient populations that may benefit most from DM199 treatment and to guide the design of upcoming Phase II studies,” said Dr. Harry Alcorn, Chief Medical Officer at DiaMedica Therapeutics.

  • GlobeNewswire

    DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders

    MINNEAPOLIS, Jan. 22, 2019 -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled  “Human Tissue Kallikrein In The Treatment Of Acute Ischemic.

  • GlobeNewswire

    DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange

    DiaMedica Therapeutics Inc. (DMAC) (DMA.V), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily delist its voting common shares from the TSX Venture Exchange. The Company’s common shares are expected to be delisted from the TSX-V at the close of business on January 18, 2019, being approximately 10 days from today's date.  DiaMedica’s shares will continue to be listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the trading symbol “DMAC.”  The Company believes that the continued listing of its common shares on the Nasdaq will provide its Canadian shareholders with a sufficiently liquid market and further, that the financial and administrative costs associated with maintaining a dual listing are not justified.

  • ACCESSWIRE

    Today's Research Reports on TSO3, Emerald Health Therapeutics, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswire

    UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (DMA.V) announced today that the U.S. Food and Drug Administration ("FDA") has accepted DiaMedica’s Investigational New Drug application ("IND") for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease (“CKD”) caused by Type I or Type II diabetes. The multi-site clinical study will enroll 32 subjects to evaluate DM199 safety, tolerability and drug levels (pharmacokinetics) in this specific population. The results from this Phase Ib study will assist DiaMedica in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD.

  • GlobeNewswire

    DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (DMA.V) announced today that the U.S. Food and Drug Administration ("FDA") has accepted DiaMedica’s Investigational New Drug application ("IND") for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease (“CKD”) caused by Type I or Type II diabetes. The multi-site clinical study will enroll 32 subjects to evaluate DM199 safety, tolerability and drug levels (pharmacokinetics) in this specific population. The results from this Phase Ib study will assist DiaMedica in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD.

  • GlobeNewswire

    DiaMedica Closes Public Offering in the United States

    TSXV:DMA), a clinical stage biopharmaceutical company, announced today that it has completed an underwritten initial public offering in the United States (the “Offering”) of 4.1 million voting common shares, no par value, of the Company (“Shares”), at a price to the public of USD$4.00 per Share. All of the Shares were issued and sold by the Company. The Shares were registered for sale pursuant to a Registration Statement on Form S-1 (Registration No. 333-228313), filed with the United States Securities and Exchange Commission and declared effective on December 6, 2018.

  • Baystreet

    Stocks in play: DiaMedica Therapeutics Inc.

    Announced today the pricing of its initial public offering in the United States of 4,100,000 of its ...

  • GlobeNewswire

    DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING

    DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its initial public offering in the United States of 4,100,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica. The common shares are expected to begin trading December 7, 2018 on The Nasdaq Capital Market under the symbol “DMAC.” The offering is expected to close on December 11, 2018, subject to the satisfaction of customary closing conditions.

  • ACCESSWIRE

    Today's Research Reports on Microbix Biosystems, Hemostemix, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswire

    DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation

    DiaMedica Therapeutics Inc. (TSX Venture:DMA) (DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list its common shares on The Nasdaq Capital Market. In connection with the planned U.S. listing, the Company, as authorized by its shareholders on November 6, 2018, is implementing a consolidation of its outstanding common shares. “We have made significant progress in positioning DM199 to treat patients with stroke and kidney diseases, including having recently announced a partnership with Ahon Pharmaceuticals, a subsidiary of Fosun Pharmaceuticals, for the treatment of acute ischemic stroke in China in an effort to deliver value to our shareholders,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer.  “This year, we have initiated a Phase II clinical study in patients who have suffered from an acute ischemic stroke and we are about to initiate a clinical study in patients with chronic kidney disease.

  • GlobeNewswire

    DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders

    MINNEAPOLIS, Nov. 06, 2018 -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its.

  • ACCESSWIRE

    Today's Research Reports on CardioComm Solutions, Sernova, Hemostemix and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 25, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...